MINDS Colloquium - Ana Andreazza - Energy metabolism and bipolar disorder: Where we are and what is coming
- Psychology, Neuroscience & Behaviour
- 09.19.2019 3:00 pm - 4:00 pm
Abstract: Mitochondria are the powerhouse of our cells. A crucial consequence of impaired mitochondrial function is damage to highly metabolically active tissues in the body. The highest energy user in the body is the brain, accounting for 20% of the total energy budget to power neuronal function, including neuronal electrical activity and neurotransmission. Continuous mitochondrial dysfunction can have profound effects on neurotransmission and may contribute substantially to changes in neuronal circuits in the brain that underlie cognition, memory and other forms of neuronal plasticity.
One plausible hypothesis is that bipolar disorder is due in part to the failure of mitochondrial function to support adequate neurotransmission and synaptic plasticity, potentially affecting mood regulation, memory, and executive function. This hypothesis is supported by studies in bipolar disorder showing higher (1) frequency of mtDNA mutations; (2) polymorphisms in autosomal mitochondrial complex I genes; (3) lactate levels; (4) reactive
oxygen species (ROS) production; and downregulation of NDUFS7 (an essential mitochondrial complex I subunit). One of the most intriguing clinical observations is that individuals with mitochondrial disease commonly present with psychiatric symptoms.
In this lecture Dr. Andreazza will provide an overview of where we are and where we re going on the study of energy metabolism in the diagnosis and treatment of bipolar disorder. She will focus on a simple question “: Is mitochondrial function the cause of neurotransmission changes in bipolar disorder?” and finish her presentation with novel models including the use of brain organdies to understand the involvement of the energy metabolism on neurotransmission.
Dr Ana Andreazza
Dr. Andreazza is an Associate Professor in the Departments of Pharmacology & Toxicology and Psychiatry and holds a holding Tier II Canada Research Chair in Molecular Pharmacology of Mood Disorders. She is cross-appointed as a collaborator Scientist at the Centre for Addiction and Mental Health. Dr. Andreazza is an Advisor for the Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, a consultant for the Bipolar Biobank at Mayo Clinic and as a member of the Board of Directors from the International Society of Bipolar Disorder.
Dr. Andreazza received PhD in Biochemistry from the Federal University of Rio Grande do Sul, RS, Brazil. She has published over 140 research articles with an h-index factor of 45. She is the recipient of several prestigious research awards, including the 2018 Canada Top 40 Under 40 and has received funding from the Brain and Behavior Foundation (NARSAD), the Canadian Institutes for Health Research, the Ontario Mental Health Foundation and the Ontario Ministry of Research and Innovation. Her research focuses on the understanding of the role of redox modulations and mitochondrial dysfunction in mental illness, especially in mood disorders.
Dr. Andreazza research focuses on the understanding of the role of mitochondrial function in mental illness, especially in mood disorders. As neurons depend on mitochondrial function, dysfunctional mitochondrial during neurodevelopment is expected to impact neurotransmission with potentially crucial implications for mood disorders. Currently, Dr. Andreazza is evaluating the impact of mitochondrial dysfunction on neurotransmission using 3D brain organoids generated from induced pluripotent stem cells from patients with bipolar disorder and/or mitochondrial disease.
To accelerate the discovery of effective therapeutic approaches to treat mitochondrial dysfunction/disease, Dr. Andreazza founded the mitoNET.ca with the objective of uniting researchers from different medical fields with a common interest in unveiling the role of mitochondrial function and genetics in human diseases.